GSK vs IBIO · P/E 13, $103.31B cap vs rev $100.0K
GlaxoSmithKline PLC ADR (GSK) versus iBio, Inc. Common Stock (IBIO) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. IBIO currently screens at market cap $13.4M.
Not investment advice. Open the GSK and IBIO stock pages for the full models.
Not investment advice.